PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
56 hedge funds and large institutions have $38.9M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
47% less capital invested
Capital invested by funds: $73.4M → $38.9M (-$34.6M)
Holders
56
Holding in Top 10
–
Calls
$118K
Puts
$14K
Top Buyers
| 1 | +$1.87M | |
| 2 | +$1.39M | |
| 3 | +$1.39M | |
| 4 |
Renaissance Technologies
New York
|
+$118K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$53.1K |
Top Sellers
| 1 | -$1.58M | |
| 2 | -$1.03M | |
| 3 | -$713K | |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$338K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$185K |